MedTrace Logo

Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant

NCT02611063 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-03-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether fostamatinib, a drug that blocks activated B cells will be effective in preventing and treating chronic graft vs host disease (cGVHD) after allogeneic stem cell transplant. Activated B cells may play a role in development of cGVHD. Inhibiting the B cell activation using fostamatinib after allogeneic stem cell transplant may prevent the development of cGVHD.

Conditions

Interventions

DRUG

fostamatinib

100mg qd, 150mg qd, or 100mg bid

Sponsors & Collaborators

  • Stefanie Sarantopoulos, MD, PhD.

    lead OTHER

Principal Investigators

  • Stefanie Sarantopoulos, MD, PhD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2021-02-28
Completion
2022-02-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02611063 on ClinicalTrials.gov